Improved MSC Minimal Criteria to Maximize Patient Safety: A Call to Embrace Tissue Factor and Hemocompatibility Assessment of MSC Products

Abstract The number of mesenchymal stromal/stem cell (MSC) therapeutics and types of clinical applications have greatly diversified during the past decade, including rapid growth of poorly regulated “Stem Cell Clinics” offering diverse “Unproven Stem Cell Interventions.” This product diversification...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Stem cells translational medicine Jg. 11; H. 1; S. 2 - 13
Hauptverfasser:	Moll, Guido, Ankrum, James A, Olson, Scott D, Nolta, Jan A
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	US Oxford University Press 03.03.2022
Schlagworte:	Blood Coagulation Case reports Clinical trials Humans Mesenchymal Stem Cell Transplantation - adverse effects Mesenchymal Stem Cells - metabolism Patient safety Stem cells Therapeutic applications Thromboembolism Thromboplastin - metabolism Tissue factor mesenchymal stromal/stem cells (MSCs) product diversification hemocompatibility thromboembolism safety and efficacy coagulopathy cellular therapy tissue source coagulation tissue factor/CD142/Factor III/F3
ISSN:	2157-6564, 2157-6580, 2157-6580
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!